Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic and in silico studies for a series of synthetic thiosemicarbazones as New Delhi metallo-beta-lactamase carbapenemase inhibitors.

Journal of biomolecular structure & dynamics - 1 Jan 2022

Moreira Jonatham Souza, Galvão Danilo Santana, Xavier Carolina Ferreira Cavalcanti, Cunha Silvio, Pita Samuel Silva da Rocha, Reis Joice Neves, Freitas Humberto Fonseca de

Abstract excerpt

The past two decades have been marked by a global spread of bacterial resistance to β-lactam drugs and carbapenems derivatives are the ultimate treatment against multidrug-resistant bacteria. β-lactamase expression is related to resistance which demands the development of bacterial resistance blockers. Drug inhibitor combinations of serine-β-lactamase and β-lactam were successful employed in therapy despite their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to beta-Lactamase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to beta-Lactamases

Share to beta-Lactams

Share to Microbial Sensitivity Tests

Share to Phenotype

Source

Identifiers

PMID: 34766882
DOI: 10.1080/07391102.2021.2001379

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic and in silico studies for a series of synthetic thiosemicarbazones as New Delhi metallo-beta-lactamase carbapenemase inhibitors.PMID 34766882Read ↗

Enzyme Inhibitors: The Best Strategy to Tackle Superbug NDM-1 and Its Variants.Semantic proximity Read ↗

β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited ResourcesSemantic proximity Read ↗

&#946;-Lactamase Inhibitors: The Story so FarSemantic proximity Read ↗

Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical UseSemantic proximity Read ↗

Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance.Semantic proximity Read ↗

Progress Toward Inhibitors of Metallo-β-LactamasesSemantic proximity Read ↗

PHT427 as an effective New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor restored the susceptibility of meropenem against Enterobacteriaceae producing NDM-1Semantic proximity Read ↗

Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase InhibitorsSemantic proximity Read ↗

Virtual screening identifies broad-spectrum β-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemasesSemantic proximity Read ↗

Tackling the Antibiotic Resistance Caused by Class A β-Lactamases through the Use of β-Lactamase Inhibitory ProteinSemantic proximity Read ↗

Evolving trends of New Delhi Metallo-betalactamse (NDM) variants: A threat to antimicrobial resistance.Semantic proximity Read ↗

Beta-lactams and Beta-lactamase-inhibitors in current- or potential-clinical practice: A comprehensive updateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.